Shawn L. Shah
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Shawn L. Shah has a total of 41 co-authors. Here are the top co-authors by number of shared publications:
- Ahmad Najdat Bazarbashi
Division of Gastroenterology, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia
1 shared publication - Alyson M. Johnson
Division of Gastroenterology, Duke University, Durham, North Carolina, USA
1 shared publication - Anand Singla
Division of Gastroenterology, University of Washington, Seattle, Washington, USA
1 shared publication - Bertrand Napoleon
Hôpital Privé Jean Mermoz, Lyon, France
1 shared publication Brian E. Lacy
Division of Gastroenterology and Hepatology, Mayo Clinic, Jacksonville, Florida
1 shared publicationChapman Michael Shane
1 shared publication
Latest Publications
- Open Access
- 26 August 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (17) , 6028
Advances in Endoscopic Diagnosis and Management of Cholangiocarcinoma
Cholangiocarcinoma (CCA) is an aggressive malignancy originating from the epithelial lining of the intrahepatic or extrahepatic bile ducts. Although rare globally, its mortality closely mirrors incidence due to late-stage presentation of the disease and limited curative options. While surgical resection and liver transplantation remain the cornerstone treatments for those with resectable disease, endoscopic techniques have emerged as versatile tools for diagnosis, therapy, and palliation. In recent years, there have been major advancements in endoscopic therapies, including radiofrequency ablation (RFA), intraluminal brachytherapy (ILBT), and photodynamic therapy (PDT). The current narrative review serves to provide an overview of current and emerging endoscopic strategies for CCA, emphasizing diagnostic capabilities, therapeutic approaches, palliative interventions, and future directions.
- 26 August 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (17) , 6028
Open AccessAdvances in Endoscopic Diagnosis and Management of Cholangiocarcinoma
Cholangiocarcinoma (CCA) is an aggressive malignancy originating from the epithelial lining of the intrahepatic or extrahepatic bile ducts. Although rare globally, its mortality closely mirrors incidence due to late-stage presentation of the disease and limited curative options. While surgical resection and liver transplantation remain the cornerstone treatments for those with resectable disease, endoscopic techniques have emerged as versatile tools for diagnosis, therapy, and palliation. In recent years, there have been major advancements in endoscopic therapies, including radiofrequency ablation (RFA), intraluminal brachytherapy (ILBT), and photodynamic therapy (PDT). The current narrative review serves to provide an overview of current and emerging endoscopic strategies for CCA, emphasizing diagnostic capabilities, therapeutic approaches, palliative interventions, and future directions.
- 9 December 2024
- Published by SAGE Publications in Foregut: The Journal of the American Foregut Society
- Vol. 5 (2) , 174-178
How I Do It: Management of Upper Gastrointestinal Perforations and Leaks
Transmural gastrointestinal (GI) tract defects are defined as a complete interruption of the gastrointestinal lumen, and can be characterized as perforations, leaks, and fistulae. Each arise from distinct mechanisms and must be managed with an approach tailored accordingly. While traditionally managed surgically, the emergence of a variety of tools and techniques have enabled endoscopists to offer a less invasive alternative to effectively manage gastrointestinal leaks and perforations. Herein, in this “How I Do It” overview, we focus on the assessment and endoscopic management of GI perforations and leaks, including device selection, adjunctive techniques, and post-procedural considerations.
- 9 December 2024
- Published by SAGE Publications in Foregut: The Journal of the American Foregut Society
- Vol. 5 (2) , 174-178
How I Do It: Management of Upper Gastrointestinal Perforations and Leaks
Transmural gastrointestinal (GI) tract defects are defined as a complete interruption of the gastrointestinal lumen, and can be characterized as perforations, leaks, and fistulae. Each arise from distinct mechanisms and must be managed with an approach tailored accordingly. While traditionally managed surgically, the emergence of a variety of tools and techniques have enabled endoscopists to offer a less invasive alternative to effectively manage gastrointestinal leaks and perforations. Herein, in this “How I Do It” overview, we focus on the assessment and endoscopic management of GI perforations and leaks, including device selection, adjunctive techniques, and post-procedural considerations.
- Open Access
- 31 May 2024
- Published by MDPI AG in Diagnostics
- Vol. 14 (11) , 1156
Role of Endoscopic Ultrasound in Pancreatic Cancer Diagnosis and Management
The emergence of endoscopic ultrasound (EUS) has significantly impacted the diagnosis and management of pancreatic cancer and its associated sequelae. While the definitive role of EUS for pancreatic cancer remains incompletely characterized by currently available guidelines, EUS undoubtedly offers high diagnostic accuracy, the precise staging of pancreatic neoplasms, and the ability to perform therapeutic and palliative interventions. However, current challenges to EUS include limited specialized expertise and variability in operator proficiency. As the technology and techniques continue to evolve and become more refined, EUS is poised to play an increasingly integral role in shaping pancreatic cancer care.
- 31 May 2024
- Published by MDPI AG in Diagnostics
- Vol. 14 (11) , 1156
Open AccessRole of Endoscopic Ultrasound in Pancreatic Cancer Diagnosis and Management
The emergence of endoscopic ultrasound (EUS) has significantly impacted the diagnosis and management of pancreatic cancer and its associated sequelae. While the definitive role of EUS for pancreatic cancer remains incompletely characterized by currently available guidelines, EUS undoubtedly offers high diagnostic accuracy, the precise staging of pancreatic neoplasms, and the ability to perform therapeutic and palliative interventions. However, current challenges to EUS include limited specialized expertise and variability in operator proficiency. As the technology and techniques continue to evolve and become more refined, EUS is poised to play an increasingly integral role in shaping pancreatic cancer care.
- 9 November 2023
- Published by Springer Nature in Current Gastroenterology Reports
- Vol. 25 (12) , 374-379
Revisiting Proton Pump Inhibitors as Chemoprophylaxis Against the Progression of Barrett’s Esophagus
Purpose of Review Barrett’s esophagus (BE) is associated with chronic gastroesophageal reflux disease and is a known precursor to esophageal adenocarcinoma. While endoscopic surveillance strategies and the role for endoscopic eradication therapy have been well established, there has been much interest in identifying chemopreventive agents to disrupt or halt the metaplasia-dysplasia-carcinoma sequence in patients with BE. Recent Findings No pharmacological agent has held more hope in reducing the risk of neoplastic progression in BE than proton pump inhibitors (PPIs). However, data supporting PPIs for chemoprevention have largely been from observational cohort and case–control studies with mixed results. Summary In this review, we revisit the literature and highlight the role of PPIs in patients with BE as it pertains to chemoprophylaxis against the progression of BE to dysplasia and esophageal adenocarcinoma.
- 9 November 2023
- Published by Springer Nature in Current Gastroenterology Reports
- Vol. 25 (12) , 374-379
Revisiting Proton Pump Inhibitors as Chemoprophylaxis Against the Progression of Barrett’s Esophagus
Purpose of Review Barrett’s esophagus (BE) is associated with chronic gastroesophageal reflux disease and is a known precursor to esophageal adenocarcinoma. While endoscopic surveillance strategies and the role for endoscopic eradication therapy have been well established, there has been much interest in identifying chemopreventive agents to disrupt or halt the metaplasia-dysplasia-carcinoma sequence in patients with BE. Recent Findings No pharmacological agent has held more hope in reducing the risk of neoplastic progression in BE than proton pump inhibitors (PPIs). However, data supporting PPIs for chemoprevention have largely been from observational cohort and case–control studies with mixed results. Summary In this review, we revisit the literature and highlight the role of PPIs in patients with BE as it pertains to chemoprophylaxis against the progression of BE to dysplasia and esophageal adenocarcinoma.
- Open Access
- 18 July 2023
- Published by Elsevier in Gastrointestinal Endoscopy
- Vol. 98 (6) , 953-964
Structured training program on confocal laser endomicroscopy for pancreatic cystic lesions: a multicenter prospective study among early-career endosonographers (with video)
- 18 July 2023
- Published by Elsevier in Gastrointestinal Endoscopy
- Vol. 98 (6) , 953-964
Open AccessStructured training program on confocal laser endomicroscopy for pancreatic cystic lesions: a multicenter prospective study among early-career endosonographers (with video)
- 1 January 2021
- Published by Elsevier in Clinical Gastroenterology and Hepatology
- Vol. 19 (1) , 80-86
Patients With Irritable Bowel Syndrome Are Willing to Take Substantial Medication Risks for Symptom Relief
- 1 January 2021
- Published by Elsevier in Clinical Gastroenterology and Hepatology
- Vol. 19 (1) , 80-86
Patients With Irritable Bowel Syndrome Are Willing to Take Substantial Medication Risks for Symptom Relief
- 1 May 2017
- Published by Wolters Kluwer Health in Pancreas
- Vol. 46 (5) , e41-e42
The Cost of Surveying Intraductal Papillary Mucinous Neoplasms
- 1 May 2017
- Published by Wolters Kluwer Health in Pancreas
- Vol. 46 (5) , e41-e42
The Cost of Surveying Intraductal Papillary Mucinous Neoplasms
- Open Access
- 31 August 2016
- Published by ClinMed International Library in Journal of Dermatology Research and Therapy
- Vol. 2 (4)
Esophagitis Dissecans Superficialis with Concomitant Bullous Pemphigoid: A Case Report
Esophagitis dissecans superficialis (EDS) is a rare endoscopic finding characterized by sloughing of the esophageal mucosal lining, which has been infrequently associated with autoimmune bullous dermatoses. We report a case of a 77-year-old man who presented with diffuse mucocutaneous bullous lesions and odynophagia. Direct immunofluorescence of a skin biopsy confirmed a diagnosis of bullous pemphigoid and esophagogastroduodenoscopy revealed linear fissures and sloughing of the esophageal mucosa consistent with a diagnosis of EDS. With only two previously reported cases of EDS associated with bullous pemphigoid, prompt endoscopic evaluation should be considered in patients with bullous lesions and gastrointestinal symptoms.
- 31 August 2016
- Published by ClinMed International Library in Journal of Dermatology Research and Therapy
- Vol. 2 (4)
Open AccessEsophagitis Dissecans Superficialis with Concomitant Bullous Pemphigoid: A Case Report
Esophagitis dissecans superficialis (EDS) is a rare endoscopic finding characterized by sloughing of the esophageal mucosal lining, which has been infrequently associated with autoimmune bullous dermatoses. We report a case of a 77-year-old man who presented with diffuse mucocutaneous bullous lesions and odynophagia. Direct immunofluorescence of a skin biopsy confirmed a diagnosis of bullous pemphigoid and esophagogastroduodenoscopy revealed linear fissures and sloughing of the esophageal mucosa consistent with a diagnosis of EDS. With only two previously reported cases of EDS associated with bullous pemphigoid, prompt endoscopic evaluation should be considered in patients with bullous lesions and gastrointestinal symptoms.
- Open Access
- 2 December 2013
- Published by Wiley in Journal of Immunology Research
- Vol. 2013, 1-7
Helicobacter pyloriInfection and Light Chain Gammopathy
Objective. Helicobacter pylori provokes a host of immune alterations upon colonizing the gastric mucosa. Design. We report 22 individuals with confirmed Helicobacter pylori infection who were also managed for the concurrent elevation of immunoglobulin free light chain (kappa and lambda) levels. Result. Of the 22 patients, 15 patients (68.2%) had elevated free light chain levels: 6 patients (40%) had only kappa chain elevation, 2 patients (13.3%) had only lambda chain elevation, and 7 patients (46.7%) had both kappa and lambda chain elevation. Twenty out of the 22 patients (90.9%) were microbiologically confirmed cured with 3 patients being lost to follow-up for repeat levels. Of the 3 patients who were lost to follow-up, 1 patient had only kappa chain elevation, 1 patient had only lambda chain elevation, and 1 patient had both kappa and lambda chain elevation. For those who were cured (19 patients), 5 patients with kappa elevation had normalized values, 4 patients with lambda elevation had normalized values, and 2 patients with combined kappa and lambda elevation had normalized values. For 6 out of the 19 patients, the light chain levels remained elevated. Conclusion. We speculate that the Helicobacter pylori infection disrupts the immunoglobulin system with potential implications being discussed below.
- 2 December 2013
- Published by Wiley in Journal of Immunology Research
- Vol. 2013, 1-7
Open AccessHelicobacter pyloriInfection and Light Chain Gammopathy
Objective. Helicobacter pylori provokes a host of immune alterations upon colonizing the gastric mucosa. Design. We report 22 individuals with confirmed Helicobacter pylori infection who were also managed for the concurrent elevation of immunoglobulin free light chain (kappa and lambda) levels. Result. Of the 22 patients, 15 patients (68.2%) had elevated free light chain levels: 6 patients (40%) had only kappa chain elevation, 2 patients (13.3%) had only lambda chain elevation, and 7 patients (46.7%) had both kappa and lambda chain elevation. Twenty out of the 22 patients (90.9%) were microbiologically confirmed cured with 3 patients being lost to follow-up for repeat levels. Of the 3 patients who were lost to follow-up, 1 patient had only kappa chain elevation, 1 patient had only lambda chain elevation, and 1 patient had both kappa and lambda chain elevation. For those who were cured (19 patients), 5 patients with kappa elevation had normalized values, 4 patients with lambda elevation had normalized values, and 2 patients with combined kappa and lambda elevation had normalized values. For 6 out of the 19 patients, the light chain levels remained elevated. Conclusion. We speculate that the Helicobacter pylori infection disrupts the immunoglobulin system with potential implications being discussed below.